Literature DB >> 25407926

[18F]fluoromethylcholine as a chemotherapy response read-out in prostate cancer cells.

Daniela E Oprea-Lager1, Mitchell P van Kanten, Reindert J A van Moorselaar, Alfons J M van den Eertwegh, Peter M van de Ven, Irene V Bijnsdorp, Otto S Hoekstra, Albert A Geldof.   

Abstract

PURPOSE: The objective of the present study is to determine whether uptake of [(18)F]fluoromethylcholine ([(18)F]FCH) in comparison with 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) accurately reflects chemotherapy efficacy at the tumor cell level in prostate cancer (PC). PROCEDURES: The effects of docetaxel and cabazitaxel on viable tumor cell number were explored in four PC cell lines. Cellular uptake of [(18)F]FDG and [(18)F]FCH was compared with the effects measured using sulforhodamine B (SRB) assay, cell counting and colony formation assay (CFA), as proximators of viable tumor cell number. Agreement between uptake and cell numbers was assessed by Bland-Altman plots.
RESULTS: [(18)F]FCH uptake in all PC cell lines significantly correlated to the cell numbers surviving the respective drug concentrations. Bland-Altman analysis showed that [(18)F]FDG uptake resulted in signal overestimation and higher variability after chemotherapy.
CONCLUSIONS: [(18)F]FCH uptake correlates well with viable tumor cell numbers remaining after docetaxel and cabazitaxel exposure. Radiolabeled choline is a potential response monitoring biomarker after chemotherapy for PC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25407926     DOI: 10.1007/s11307-014-0803-7

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  42 in total

1.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

2.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

Review 3.  End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice.

Authors:  Howard I Scher; Michael J Morris; Ethan Basch; Glenn Heller
Journal:  J Clin Oncol       Date:  2011-08-22       Impact factor: 44.544

4.  Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.

Authors:  Colleen M Costelloe; Hubert H Chuang; John E Madewell; Naoto T Ueno
Journal:  J Cancer       Date:  2010-06-28       Impact factor: 4.207

5.  The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.

Authors:  Mohsen Beheshti; Reza Vali; Peter Waldenberger; Friedrich Fitz; Michael Nader; Josef Hammer; Wolfgang Loidl; Christian Pirich; Ignac Fogelman; Werner Langsteger
Journal:  Mol Imaging Biol       Date:  2009 Nov-Dec       Impact factor: 3.488

6.  Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study.

Authors:  Mohsen Beheshti; Reza Vali; Peter Waldenberger; Friedrich Fitz; Michael Nader; Wolfgang Loidl; Gabriele Broinger; Franz Stoiber; Ignac Foglman; Werner Langsteger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-09       Impact factor: 9.236

7.  Functional analysis of [methyl-(3)H]choline uptake in glioblastoma cells: Influence of anti-cancer and central nervous system drugs.

Authors:  Chiaki Taguchi; Masato Inazu; Iwao Saiki; Miki Yara; Naomi Hara; Tsuyoshi Yamanaka; Hiroyuki Uchino
Journal:  Biochem Pharmacol       Date:  2014-02-12       Impact factor: 5.858

8.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

Authors:  Dominik R Berthold; Gregory R Pond; Freidele Soban; Ronald de Wit; Mario Eisenberger; Ian F Tannock
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

9.  [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.

Authors:  Marino Cimitan; Roberto Bortolus; Sandro Morassut; Vincenzo Canzonieri; Antonio Garbeglio; Tanja Baresic; Eugenio Borsatti; Annalisa Drigo; Mauro G Trovò
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-25       Impact factor: 10.057

10.  Choline PET and PET/CT in Primary Diagnosis and Staging of Prostate Cancer.

Authors:  S Schwarzenböck; M Souvatzoglou; B J Krause
Journal:  Theranostics       Date:  2012-03-15       Impact factor: 11.556

View more
  5 in total

1.  Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT.

Authors:  Joohee Lee; Miles M Sato; Marc N Coel; Kyung-Han Lee; Sandi A Kwee
Journal:  J Nucl Med       Date:  2016-02-16       Impact factor: 10.057

2.  Recapitulating Tumor Hypoxia in a Cleanroom-Free, Liquid-Pinning-Based Microfluidic Tumor Model.

Authors:  Jeong Min Oh; Hydari Masuma Begum; Yao Lucia Liu; Yuwei Ren; Keyue Shen
Journal:  ACS Biomater Sci Eng       Date:  2022-06-09

3.  Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study.

Authors:  Lavinia Vija Racaru; Mathieu Sinigaglia; Salim Kanoun; Fayçal Ben Bouallègue; Ilan Tal; Sévérine Brillouet; Mathilde Bauriaud-Mallet; Slimane Zerdoud; Lawrence Dierickx; Delphine Vallot; Olivier Caselles; Erwan Gabiache; Pierre Pascal; Frederic Courbon
Journal:  Nucl Med Commun       Date:  2018-07       Impact factor: 1.690

Review 4.  Nuclear Imaging for Bone Metastases in Prostate Cancer: The Emergence of Modern Techniques Using Novel Radiotracers.

Authors:  Wietske I Luining; Dennie Meijer; Max R Dahele; André N Vis; Daniela E Oprea-Lager
Journal:  Diagnostics (Basel)       Date:  2021-01-13

5.  18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready?

Authors:  Luca Urso; Federica Lancia; Naima Ortolan; Marta Frapoli; Martina Rauso; Paolo Artioli; Corrado Cittanti; Licia Uccelli; Antonio Frassoldati; Laura Evangelista; Mirco Bartolomei
Journal:  Clin Transl Imaging       Date:  2022-07-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.